Research programme: protein serine threonine kinase inhibitors - Myrexis

Drug Profile

Research programme: protein serine threonine kinase inhibitors - Myrexis

Alternative Names: MPI-0485520; MPI-485520

Latest Information Update: 26 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer; Inflammation; Rheumatoid arthritis

Highest Development Phases

  • Suspended Cancer; Diabetes mellitus; Inflammation; Obesity; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 MPI 485520 is available for licensing (www.myrexis.com)
  • 26 May 2011 Preclinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top